Get started
Author

Xuening Ji

Observed names: Ji, Xuening, XUE-NING JI, Xue-Ning Ji
ORCID: 0000-0002-0732-8274
Observed ORCID: 0000-0002-0732-8274
OpenAlex ID: A5015595184
A decade?s studies on metastasis of hepatocellular carcinoma
2004 · Zhao-You Tang, Sheng-Long Ye, et al. · Journal of Cancer Research and Clinical Oncology · 421
Prognostic significance of PD‐L1 expression on cell‐surface vimentin‐positive circulating tumor cells in gastric cancer patients
2020 · Mengyuan Liu, Ruoyu Wang, et al. · Molecular Oncology · 60
PDF
Basement membrane proteins play an active role in the invasive process of human hepatocellular carcinoma cells with high metastasis potential
2004 · Bo Tian, Yan Li, et al. · Journal of Cancer Research and Clinical Oncology · 51
Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression
2015 · Xuening Ji, Shi Jin, et al. · BMC Cancer · 50
PDF
HOXB9 promotes epithelial-to-mesenchymal transition via transforming growth factor-β1 pathway in hepatocellular carcinoma cells
2014 · Lin Sha, Lei Dong, et al. · Clinical and Experimental Medicine · 38
Contributions of lung tissue extracts to invasion and migration of human hepatocellular carcinoma cells with various metastatic potentials
2003 · Xue-Ning Ji, Sheng-Long Ye, et al. · Journal of Cancer Research and Clinical Oncology · 18
Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer
2015 · Heming Li, Tong Zhao, et al. · Tumor Biology · 14
Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
2020 · Yizhao Xie, Rui Ge, et al. · Cancer Medicine · 12
PDF
Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer
2022 · Lanxin Zhang, Siwen Sun, et al. · Molecular Oncology · 11
PDF
Homeobox B9 is overexpressed in hepatocellular carcinomas and promotes tumor cell proliferation both in vitro and in vivo
2014 · Fangyi Li, Lei Dong, et al. · Biochemical and Biophysical Research Communications · 11
The prognostic role of a combined fibrinogen and inflammation- based index in patients with metastatic breast cancer
2020 · Qiuge Liu, Shuangshuang Fang, et al. · Translational Cancer Research · 9
PDF
Effect of fractionated irradiation on the expression of multidrug resistance genes in the CNE1 human nasopharyngeal carcinoma cell line
2012 · XUE-NING JI, FANG YANG, et al. · Molecular Medicine Reports · 9
PDF
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence Trial
2024 · Shaohua Zhang, Yongmei Yin, et al. · JAMA Oncology · 8
PDF
Patient-derived organoid elucidates the identical clonal origin of bilateral breast cancer with diverse molecular subtypes
2024 · Zhongbin Han, Liangxue Yao, et al. · Frontiers in Oncology · 7
Establishment of a Model of Microencapsulated SGC7901 Human Gastric Carcinoma Cells Cocultured with Tumor-Associated Macrophages
2018 · Jin-Ming Zhu, Xiu-Lian Quan, et al. · Canadian Journal of Gastroenterology and Hepatology · 4
PDF
Trametes robiniophila may induce apoptosis and inhibit MMPs expression in the human gastric carcinoma cell line MKN-45
2016 · Xuening Ji, Chunxia Pan, et al. · Oncology Letters · 4
PDF
Pyrotinib and Nab‐Paclitaxel in HER2 ‐Positive Breast Cancer ( PANHER Trial): A Prospective, Single‐Arm, Phase II Trial
2025 · Huan Li, Min Yan, et al. · Cancer Science · 2
A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2− breast cancer in China
2026 · Quchang Ouyang, Peng Yuan, et al. · The Oncologist · 1
Time to treatment failure (TTF) and overall survival (OS) with palbociclib (PAL) plus endocrine therapy (ET) versus ET in HR+/HER2- advanced breast cancer (ABC) patients: A real-world multicenter study from China.
2023 · Lanxin Zhang, Fengxi Chen, et al. · Journal of Clinical Oncology · 1
PDF
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
2022 · Min Yan, Peng Yuan, et al. · Therapeutic Advances in Medical Oncology · 1
Capivasertib plus fulvestrant in Chinese patients with HR+/HER2− advanced breast cancer: Interim analysis of CAPItrue.
2026 · Peng Yuan, Zhanhong Chen, et al. · Journal of Clinical Oncology
Pyrotinib plus nab-paclitaxel in patients with HER2-positive advanced or metastatic breast cancer: A multicenter, single-arm, open-label phase 2 trial.
2022 · Huan Li, Zhaohui Li, et al. · Journal of Clinical Oncology
Clinical outcomes and clinical/genetic risk factors of palbociclib plus endocrine therapy (ET) for HR+HER2− advanced breast cancer (ABC) patients in Chinese multicenter study of real-world practices.
2022 · Lanxin Zhang, Haibo Wang, et al. · Journal of Clinical Oncology
Abstract 2288: Cell-surface vimentin as a novel biomarker for detecting circulating tumor cells from advanced gastric cancer patients
2019 · Heming Li, Yuting Liu, et al. · Cancer Research
Abstract 2288: Cell-surface vimentin as a novel biomarker for detecting circulating tumor cells from advanced gastric cancer patients
2019 · Heming Li, Yuting Liu, et al. · Clinical Research (Excluding Clinical Trials)
Works count: 31
Citation count: 732
H-index: 10
I10-index: 10
Year
Topic
Type